Determinants of the level of anti-SARSCoV- 2 IgG ANTibodiEs after vaccination (DANTE-SIRIO 7) study. A rationale and protocol of the study
Abstract
Introduction: Great expectations to control the pandemic are placed on vaccines against COVID-19. So far, four COVID-19 vaccines have been approved for use in the European Union. This study aimed to assess the anti-SARS-CoV-2 IgG antibody concentration after the vaccination cycle with the BNT162b2 vaccine at several predefined time points. All results will be compared to the COVID-19 history and severity of symptoms during the disease and after the first and second vaccine dose. Material and methods: The study includes healthy, unselected volunteers from the staff of Dr. Antoni Jurasz University Hospital No.1 in Bydgoszcz and students of the Collegium Medicum, Nicolaus Copernicus University. To meet the inclusion criteria all individuals will have to be vaccinated with two doses of the BNT162b2 (BioNTech/Pfizer, US) vaccine. Anti-SARS-CoV-2 IgG antibody concentrations will be measured in fresh serum samples collected from each participant at predefined time points. All measurements will be performed using the Atellica system (Siemens Healthineers, Erlangen, Germany). Results of SARS-CoV-2 IgG are given as U/mL, whereby the cut-off for positivity is defined as ≥ 1.0 U/mL. Discussion: This study was designed to evaluate the impact of COVID-19 on the severity of clinical symptoms and the levels of anti-SARS-CoV-2 IgG antibodies after vaccination. Hopefully, based on its results, further clinical outcome-powered trials will be designed and conducted to elucidate how quantitative antibody levels can be used as a correlate of vaccine-mediated protection.
Keywords: SARS-CoV-2COVID- 19anti-SARS-CoV-2 IgG antibodiesCOVID-19 vaccine
References
- Tsai SC, Lu CC, Bau DT, et al. Approaches towards fighting the COVID‑19 pandemic (Review). Int J Mol Med. 2021; 47(1): 3–22.
- COVID-19 vaccines authorised for use in the European Union. https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-vaccines.
- Lumley SF, O'Donnell D, Stoesser NE, et al. Oxford University Hospitals Staff Testing Group. Antibody status and incidence of SARS-CoV-2 infection in health care workers. N Engl J Med. 2021; 384(6): 533–540.
- Lombardi A, Bozzi G, Ungaro R, et al. Mini review immunological consequences of immunization with COVID-19 mRNA vaccines: preliminary results. Front Immunol. 2021; 12: 657711.
- Baden LR, El Sahly HM, Essink B, et al. COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021; 384(5): 403–416.
- Polack FP, Thomas SJ, Kitchin N, et al. C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020; 383(27): 2603–2615.
- Lombardi A, Consonni D, Oggioni M, et al. SARS-CoV-2 anti-spike antibody titres after vaccination with BNT162b2 in naïve and previously infected individuals. J Infect Public Health. 2021; 14(8): 1120–1122.
- Grzelakowska K, Kryś J. The impact of COVID-19 on healthcare workers’ absenteeism: infections, quarantines, sick leave — a database analysis of the Antoni Jurasz University Hospital No. 1. in Bydgoszcz, Poland. Medical Research Journal. 2021; 6(1): 47–52.
- Lackowski P, Piasecki M, Kasprzak M, et al. COVID-19 pandemic year in the cardiology department. Medical Research Journal. 2021; 6(1): 40–46.
- Grzelakowska K, Kasprzak M, Kryś J. COVID-19 and diabetes: a deadly duo? Medical Research Journal. 2021; 6(2): 119–124.